**This Weight-Loss Solution Becomes India’s Second-Highest Selling Drug**
*By Dwaipayan Roy | Oct 08, 2025, 05:14 PM*
Eli Lilly’s anti-obesity and diabetes drug, **Mounjaro**, has quickly made a remarkable impact on the Indian pharmaceutical market. Within just six months of its launch, Mounjaro has climbed to become the second-best selling drug in India, riding the wave of increasing demand for effective weight-loss therapies across the country.
### Market Performance: Rapid Sales Growth
According to data from the Indian Pharmaceutical Market (IPM), Mounjaro recorded sales worth ₹80 crore in September alone and has generated total revenue of ₹233 crore since its debut. The drug experienced an impressive 43% sales growth from August to September, positioning it as a strong competitor to GSK’s Augmentin, which currently leads the market with ₹85 crore in monthly retail sales.
Analysts highlight Mounjaro’s user-friendly pen formulation as a key factor behind its success. Furthermore, recent Goods and Services Tax (GST) cuts on pharmaceutical products are expected to bolster the drug’s sales momentum even further in the coming months.
### Product Details: High Efficacy and Convenient Dosage
Mounjaro offers a promising weight-loss efficacy rate of 20-22%, making it a potent option for patients battling obesity and diabetes. Launched in India in late March 2025, the drug received a significant boost after the introduction of its injectable **Kwikpens** in August.
These disposable, pre-filled pens provide ease of use and come in a price range between ₹14,000 and ₹27,500, depending on the prescribed dosage. The convenience of the Kwikpens has been widely appreciated by patients, contributing to the product’s growing popularity.
### Sales Forecast: GST Cuts to Accelerate Growth
The recent reduction in GST on chronic care medications from 18% to 5%, effective September 22, 2025, has considerably eased the financial burden on patients requiring long-term treatment. This favorable tax cut is anticipated to further drive the adoption of Mounjaro, enhancing its sales trajectory in the near future.
As demand for weight-loss and diabetes management solutions continues to rise, Mounjaro is well-positioned to solidify its place as a flagship product in India’s pharmaceutical landscape.
https://www.newsbytesapp.com/news/business/eli-lilly-s-mounjaro-becomes-2nd-best-selling-drug-in-india/story
